Swiss National Bank’s Medpace MEDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $24.3M | Buy |
45,840
+1,360
| +3% | +$628K | 0.01% | 630 |
|
|
2026
Q1 | $21.4M | Buy |
44,480
+160
| +0.4% | +$81.9K | 0.01% | 639 |
|
|
2025
Q4 | $24.9M | Sell |
44,320
-3,080
| -6% | -$1.75M | 0.01% | 591 |
|
|
2025
Q3 | $24.4M | Sell |
47,400
-1,700
| -3% | -$742K | 0.01% | 585 |
|
|
2025
Q2 | $15.4M | Sell |
49,100
-2,100
| -4% | -$630K | 0.01% | 719 |
|
|
2025
Q1 | $15.6M | Sell |
51,200
-600
| -1% | -$202K | 0.01% | 691 |
|
|
2024
Q4 | $17.2M | Buy |
51,800
+300
| +0.6% | +$102K | 0.01% | 692 |
|
|
2024
Q3 | $17.2M | Sell |
51,500
-300
| -0.6% | -$114K | 0.01% | 690 |
|
|
2024
Q2 | $21.3M | Buy |
51,800
+3,400
| +7% | +$1.35M | 0.01% | 621 |
|
|
2024
Q1 | $19.6M | Buy |
48,400
+200
| +0.4% | +$70.3K | 0.01% | 650 |
|
|
2023
Q4 | $14.8M | Sell |
48,200
-5,500
| -10% | -$1.48M | 0.01% | 709 |
|
|
2023
Q3 | $13M | Hold |
53,700
| – | – | 0.01% | 773 |
|
|
2023
Q2 | $12.9M | Hold |
53,700
| – | – | 0.01% | 782 |
|
|
2023
Q1 | $10.1M | Sell |
53,700
-6,200
| -10% | -$1.28M | 0.01% | 859 |
|
|
2022
Q4 | $12.7M | Sell |
59,900
-900
| -1% | -$180K | 0.01% | 799 |
|
|
2022
Q3 | $9.56M | Sell |
60,800
-5,600
| -8% | -$894K | 0.01% | 900 |
|
|
2022
Q2 | $9.94M | Sell |
66,400
-1,600
| -2% | -$232K | 0.01% | 926 |
|
|
2022
Q1 | $11.1M | Buy |
68,000
+4,900
| +8% | +$808K | 0.01% | 962 |
|
|
2021
Q4 | $13.7M | Sell |
63,100
-500
| -0.8% | -$105K | 0.01% | 844 |
|
|
2021
Q3 | $12M | Buy |
63,600
+600
| +1% | +$109K | 0.01% | 903 |
|
|
2021
Q2 | $11.1M | Sell |
63,000
-2,400
| -4% | -$414K | 0.01% | 958 |
|
|
2021
Q1 | $10.7M | Buy |
65,400
+1,300
| +2% | +$199K | 0.01% | 965 |
|
|
2020
Q4 | $8.92M | Hold |
64,100
| – | – | 0.01% | 1001 |
|
|
2020
Q3 | $7.16M | Sell |
64,100
-400
| -0.6% | -$46.3K | 0.01% | 974 |
|
|
2020
Q2 | $6M | Buy |
64,500
+8,600
| +15% | +$732K | 0.01% | 1043 |
|
|
2020
Q1 | $4.1M | Buy |
55,900
+1,200
| +2% | +$104K | ﹤0.01% | 1037 |
|
|
2019
Q4 | $4.6M | Buy |
54,700
+800
| +1% | +$61.9K | ﹤0.01% | 1210 |
|
|
2019
Q3 | $4.53M | Buy |
53,900
+800
| +2% | +$60.4K | ﹤0.01% | 1155 |
|
|
2019
Q2 | $3.47M | Buy |
53,100
+4,400
| +9% | +$254K | ﹤0.01% | 1345 |
|
|
2019
Q1 | $2.87M | Buy |
48,700
+1,500
| +3% | +$89.6K | ﹤0.01% | 1430 |
|
|
2018
Q4 | $2.5M | Sell |
47,200
-1,600
| -3% | -$87.8K | ﹤0.01% | 1425 |
|
|
2018
Q3 | $2.92M | Buy |
48,800
+32,600
| +201% | +$1.78M | ﹤0.01% | 1462 |
|
|
2018
Q2 | $697K | Hold |
16,200
| – | – | ﹤0.01% | 2346 |
|
|
2018
Q1 | $566K | Buy |
16,200
+1,800
| +13% | +$65.8K | ﹤0.01% | 2334 |
|
|
2017
Q4 | $522K | Buy |
14,400
+1,000
| +7% | +$35.1K | ﹤0.01% | 2397 |
|
|
2017
Q3 | $427K | Hold |
13,400
| – | – | ﹤0.01% | 2416 |
|
|
2017
Q2 | $389K | Hold |
13,400
| – | – | ﹤0.01% | 2473 |
|
|
2017
Q1 | $400K | Hold |
13,400
| – | – | ﹤0.01% | 2435 |
|
|
2016
Q4 | $483K | Buy |
+13,400
| New | +$446K | ﹤0.01% | 2410 |
|
Other funds holding MEDP
WA
Swiss National Bank's MEDP Position: Q2 2026 in Review
Swiss National Bank increased its Medpace (MEDP) stake by 3.1% in Q2 2026, buying an estimated $628K and bringing the position to 45,840 shares worth $24.3M. The position accounts for 0.01% of the portfolio, ranked #630.
Swiss National Bank first reported a position in MEDP in Q4 2016 and has held it in 39 quarters since. The position peaked at $24.9M in Q4 2025. 695 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.
- Swiss National Bank held 45,840 shares of Medpace worth $24.3M as of Q2 2026.
- Swiss National Bank bought 1,360 Medpace shares in Q2 2026, an estimated $628K.
- Medpace made up 0.01% of Swiss National Bank's portfolio in Q2 2026, its #630 holding.
- Swiss National Bank first reported a position in Medpace in Q4 2016 and has held it in 39 quarters since.
- Swiss National Bank's Medpace position peaked at $24.9M in Q4 2025.
- 695 funds tracked by Wall St. Rank held Medpace as of Q2 2026.
Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.